Enveric Biosciences Inc vs Edwards Lifesciences Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 7390.1× Enveric Biosciences Inc's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | EW | |
|---|---|---|
Market Cap | $6.69M | $49.44B |
Volume | 41,141 | 3,508,027 |
Sector | Health | Health |
52-Week High | $10.80 | $95.18 |
52-Week Low | $1.27 | $72.65 |
Typical Hold Time | 14 Days | — |
Enterprise Value | -$1.60M | $45.90B |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
No Aura AI signal available yet.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →